Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Keyphrases

• IgA Nephropathy (IgAN) 100%
• Phase II Trial 100%
• Irbesartan 100%
• Proteinuria 58%
• Estimated Glomerular Filtration Rate 25%
• Kidney Function 16%
• Once-daily 16%
• Kidney Failure 16%
• Target Dose 16%
• All-cause Mortality 8%
• Asia 8%
• Endothelin-1 (ET-1) 8%
• Europe 8%
• Relative Risk 8%
• Least Mean Square 8%
• Well-balancing 8%
• Single Molecule 8%
• Rate of Change 8%
• Renin-angiotensin System 8%
• Rate Reduction 8%
• Angiotensin Receptor Blockers 8%
• Treatment Group 8%
• Interim Analysis 8%
• Rate Change 8%
• Randomized Methods 8%
• Efficacy Outcomes 8%
• Ratio of Means 8%
• Safety Analysis 8%
• Clinical Site 8%
• Tolerability 8%
• Estimated Glomerular Filtration Rate Decline 8%
• End-stage Kidney Disease 8%
• Phase II Study 8%
• Treatment-related Adverse Events 8%
• Change from Baseline 8%
• Biopsy-proven 8%
• One Dose 8%
• Protein-to-creatinine Ratio 8%
• Permuted Block Randomization 8%
• Angiotensin Receptor Antagonists 8%
• Efficacy Analysis 8%
• Safety Signal 8%
• Kidney Outcomes 8%

Medicine and Dentistry

• Immunoglobulin A Nephropathy 100%
• Irbesartan 100%
• Sparsentan 100%
• Proteinuria 58%
• Glomerular Filtration Rate 33%
• Kidney Function 16%
• Renal Failure 16%
• Angiotensin Receptor Antagonist 16%
• All Cause Mortality 8%
• Endothelin 8%
• Adverse Event 8%
• Creatinine 8%
• Immunosuppressive Drug 8%
• End Stage Renal Disease 8%
• Least Square Analysis 8%
• Interim Analysis 8%
• Biopsy Technique 8%
• Treatment Group 8%

Pharmacology, Toxicology and Pharmaceutical Science

• Immunoglobulin A Nephropathy 100%
• Irbesartan 100%
• Proteinuria 58%
• Angiotensin Receptor Antagonist 16%
• Kidney Failure 16%
• All Cause Mortality 8%
• Adverse Event 8%
• Immunosuppressive Agent 8%
• End Stage Renal Disease 8%
• Creatinine 8%
• Tolerability 8%
• Endothelin 8%
• Treatment Group 8%